We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Zimmer (ZBH) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
In its upcoming report, Zimmer Biomet (ZBH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.75 per share, reflecting an increase of 6.1% compared to the same period last year. Revenues are forecasted to be $1.8 billion, representing a year-over-year increase of 2.9%.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Zimmer metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts predict that the 'Net Sales- Knees' will reach $737.94 million. The estimate suggests a change of +4.5% year over year.
The consensus among analysts is that 'Net Sales- Other' will reach $153.80 million. The estimate suggests a change of -3.2% year over year.
Analysts expect 'Net Sales- S.E.T' to come in at $440.01 million. The estimate suggests a change of +4% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- Hips' of $477.65 million. The estimate indicates a change of +2.7% from the prior-year quarter.
Analysts forecast 'Net Sales- Knees- International' to reach $310.12 million. The estimate suggests a change of +5.8% year over year.
The average prediction of analysts places 'Net Sales- Hips- International' at $227.91 million. The estimate indicates a change of +2.3% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- International' reaching $751.89 million. The estimate points to a change of +4.1% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Hips- United States' should come in at $248.79 million. The estimate suggests a change of +2.6% year over year.
It is projected by analysts that the 'Net Sales- United States' will reach $1.07 billion. The estimate indicates a change of +3.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Sales- Knees- United States' should arrive at $428.57 million. The estimate indicates a change of +3.7% from the prior-year quarter.
Over the past month, shares of Zimmer have returned -4% versus the Zacks S&P 500 composite's +1.7% change. Currently, ZBH carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Zimmer (ZBH) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
In its upcoming report, Zimmer Biomet (ZBH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.75 per share, reflecting an increase of 6.1% compared to the same period last year. Revenues are forecasted to be $1.8 billion, representing a year-over-year increase of 2.9%.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Zimmer metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts predict that the 'Net Sales- Knees' will reach $737.94 million. The estimate suggests a change of +4.5% year over year.
The consensus among analysts is that 'Net Sales- Other' will reach $153.80 million. The estimate suggests a change of -3.2% year over year.
Analysts expect 'Net Sales- S.E.T' to come in at $440.01 million. The estimate suggests a change of +4% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- Hips' of $477.65 million. The estimate indicates a change of +2.7% from the prior-year quarter.
Analysts forecast 'Net Sales- Knees- International' to reach $310.12 million. The estimate suggests a change of +5.8% year over year.
The average prediction of analysts places 'Net Sales- Hips- International' at $227.91 million. The estimate indicates a change of +2.3% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- International' reaching $751.89 million. The estimate points to a change of +4.1% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Hips- United States' should come in at $248.79 million. The estimate suggests a change of +2.6% year over year.
It is projected by analysts that the 'Net Sales- United States' will reach $1.07 billion. The estimate indicates a change of +3.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Sales- Knees- United States' should arrive at $428.57 million. The estimate indicates a change of +3.7% from the prior-year quarter.
View all Key Company Metrics for Zimmer here>>>
Over the past month, shares of Zimmer have returned -4% versus the Zacks S&P 500 composite's +1.7% change. Currently, ZBH carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>